Accounting
27th Edition
ISBN: 9781337272094
Author: WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher: Cengage Learning,
expand_more
expand_more
format_list_bulleted
Question
Chapter 13, Problem 13.1CP
To determine
Ethics case:
To describe and justify: Whether Person T is behaving ethically.
Expert Solution & Answer
Want to see the full answer?
Check out a sample textbook solution
Students have asked these similar questions
Tommy Gunn is a division manager for K-Cern Inc., a small pharmaceutical company. Tommy's division has been working on a new drug that has the potential to revolutionize the treatment of skin cancer. Once the drug is proven to be effective in clinical trials, it will be approved for sale by the government and patented by the company. Because of the potential market for this drug, it is highly likely that the company's revenues and net income will increase significantly when it is approved. Tommy recently saw an internal company memo indicating that the drug passed its final clinical trial and that the company has received government approval to sell the drug. The company will issue a press release announcing this news in the next two days, and this announcement is expected to result in a dramatic increase in the company's stock price. Tommy knows that there is “free money” to be made if he invests in the stock before the announcement is made. However, K-Cern has a strict policy against…
Tommy Gunn is a division manager for K-Cern Inc., a small pharmaceutical company. Tommy's division has been working on a new drug that has the potential to revolutionize the treatment of skin cancer. Once the drug is proven to be effective in clinical trials, it will be approved for sale by the government and patented by the company. Because of the potential market for this drug, it is highly likely that the company's revenues and net income will increase significantly when it is approved. Tommy recently saw an internal company memo indicating that the drug passed its final clinical trial and that the company has received government approval to sell the drug. The company will issue a press release announcing this news in the next two days, and this announcement is expected to result in a dramatic increase in the company's stock price. Tommy knows that there is “free money” to be made if he invests in the stock before the announcement is made. However, K-Cern has a strict policy against…
Harriet Moore is an accountant for New World Pharmaceuticals. Her duties include tracking research and development spending in the new product development division. Over the course of the past six months, Harriet has noticed that a great deal of funds have been spent on a particular project for a new drug. She hears “through the grapevine” that the company is about to patent the drug and expects it to be a major advance in antibiotics. Harriet believes that this new drug will greatly improve company performance and will cause the company’s stock to increase in value. Harriet decides to purchase shares of New World in order to benefit from this expected increase. Required What are Harriet’s ethical responsibilities, if any, with respect to the information she has learned through her duties as an accountant for New World Pharmaceuticals? What are the implications of her planned purchase of New World shares?
Chapter 13 Solutions
Accounting
Ch. 13 - Of two corporations organized at approximately the...Ch. 13 - Prob. 2DQCh. 13 - A corporation with both preferred stock and common...Ch. 13 - An owner of 2,500 shares of Simmons Company common...Ch. 13 - Prob. 5DQCh. 13 - What is the primary purpose of a stock split?Ch. 13 - Prob. 7DQCh. 13 - The treasury stock in Discussion Question 7 is...Ch. 13 - What are the three classifications of restrictions...Ch. 13 - Indicate how prior period adjustments should he...
Ch. 13 - A Dividends per share Reinhardt Furniture Company...Ch. 13 - Dividends per share Zero Calories Company has...Ch. 13 - Entries for issuing stock On May 23, Stoltz Realty...Ch. 13 - Entries for issuing stock On January 22, Zentric...Ch. 13 - Prob. 13.3APECh. 13 - Entries for cash dividends The declaration,...Ch. 13 - Prob. 13.4APECh. 13 - Entries for stock dividends Antique Buggy...Ch. 13 - Prob. 13.5APECh. 13 - Entries for treasury stock On May 27, Hydro...Ch. 13 - Reporting stockholders' equity Using the following...Ch. 13 - Reporting stockholders' equity Using the following...Ch. 13 - Retained earnings statement Rockwell Inc. reported...Ch. 13 - Retained earnings statement None Cruises Inc....Ch. 13 - Earnings per share Financial statement data for...Ch. 13 - Earnings per share Financial statement data for...Ch. 13 - Dividends per share Imaging Inc., a developer of...Ch. 13 - Dividends per share Lightfoot Inc., a software...Ch. 13 - Prob. 13.3EXCh. 13 - Prob. 13.4EXCh. 13 - Issuing stock for assets other than cash On April...Ch. 13 - Prob. 13.6EXCh. 13 - Issuing stock Willow Creek Nursery, with an...Ch. 13 - Issuing stock Work Place Products Inc., a...Ch. 13 - Entries for cash dividends The declaration,...Ch. 13 - Prob. 13.10EXCh. 13 - Prob. 13.11EXCh. 13 - Prob. 13.12EXCh. 13 - Prob. 13.13EXCh. 13 - Prob. 13.14EXCh. 13 - Treasury stock transactions Lawn Spray Inc....Ch. 13 - Prob. 13.16EXCh. 13 - Reporting paid-in capital The following accounts...Ch. 13 - Stockholders' Equity section of balance sheet The...Ch. 13 - Prob. 13.19EXCh. 13 - Retained earnings statement Sumter Pumps...Ch. 13 - Prob. 13.21EXCh. 13 - Statement of stockholders' equity The...Ch. 13 - EPS Junkyard Am, Inc., had earnings of 516,000 for...Ch. 13 - Prob. 13.24EXCh. 13 - EPS Caterpillar Inc. and Deere Company are two...Ch. 13 - Prob. 13.1APRCh. 13 - Prob. 13.2APRCh. 13 - Selected stock transactions The following selected...Ch. 13 - Entries for selected corporate transactions Morrow...Ch. 13 - Entries for selected corporate transactions...Ch. 13 - Prob. 13.1BPRCh. 13 - Stock transaction for corporate expansion Pulsar...Ch. 13 - Selected stock transactions Diamondback Welding ...Ch. 13 - Entries for selected corporate transactions Nav-Go...Ch. 13 - Entries for selected corporate transactions West...Ch. 13 - Prob. 13.1CPCh. 13 - Prob. 13.2CPCh. 13 - Communication Motion Designs Inc. has paid...Ch. 13 - Prob. 13.5CPCh. 13 - Prob. 13.6CP
Knowledge Booster
Similar questions
- Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, describes itself in a recent annual report as follows. Noven Pharmaceuticals, Inc. Noven is a place of ideas—a company where scientific excellence and state-of-the-art manufacturing combine to create new answers to human needs. Our transdermal delivery systems speed drugs painlessly and effortlessly into the bloodstream by means of a simple skin patch. This technology has proven applications in estrogen replacement, but at Noven we are developing a variety of systems incorporating bestselling drugs that fight everything from asthma, anxiety and dental pain to cancer, heart disease and neurological illness. Our research portfolio also includes new technologies, such as iontophoresis, in which drugs are delivered through the skin by means of electrical currents, as well as products that could satisfy broad consumer needs, such as our anti-microbial mouthrinse. Noven also reported in its annual report that its activities to…arrow_forwardMillennium Pharmaceuticals, Inc. (MPI), designs and manufactures a variety of drugs. One new drug, Glaxane, has been in development for seven years. FDA approval has just been received, and MPI is ready to begin production and sales. Required: Refer to Exhibit 2.5. Which costs in the value chain would be considered by each of the following managers in their decision regarding Glaxane? 1. Shelly Roberts is plant manager of the New Bern, North Carolina, plant where Glaxane will be produced. Shelly has been assured that Glaxane capsules will use well-understood processes and not require additional training or capital investment. 2. Leslie Bothan is vice president of marketing. Leslies job involves pricing and selling Glaxane. Because Glaxane is the first drug in its drug family to be commercially produced, there is no experience with potential side effects. Extensive testing did not expose any real problems (aside from occasional heartburn and insomnia), but the company could not be sure that such side effects did not exist. 3. Dante Fiorello is chief of research and development. His charge is to ensure that all research projects, taken as a whole, eventually produce drugs that can support the RD labs. He is assessing the potential for further work on drugs in the Glaxane family.arrow_forwardPfizer is currently in the process of creating and producing life-saving medicines and medical devices for people in need. As an industry leader, Pfizer employs a number of scientists and doctors that research and test potential new medications and medical self-testing technologies. These research teams incurred $1,040,000 in salaries and $2,264,300 in laboratory rent during 2021. Once there are feasible production plans in place and a customer base has been identified and vetted, the development team works on producing and testing prototypes. The cost of development activities for 2021 amounts to $7,550,000 and there are several projects with fair values amounting to $5,230,400 planned and scheduled for 2022. Part of the total 2021 development costs includes $995,000 for routine alternations to the manufacturing processes. As the year-end approaches, Pfizer must begin the closing process to produce their 2021 U.S. GAAP financial statements. what is the problem statementarrow_forward
- Khair Ltd carries out research and development on a continuousbasis. The directors of the company are passionate aboutimproving their medicinal drugs and finding new cures.In the current financial year, the company has been makingsignificant findings regarding a vaccine for the coronavirus. To thiseffect, they have registered a patent for a new vaccine that willsoon be available to customers. The following costs have beenincurred in respect of the patent in the current financial year.Research salaries R250 000Development salaries R450 000Initial marketing costs R30 000Fees to register patent R78 000Materials used in development R12 000The development was completed on 1 July 2020.Patents are amortised on a straight‐line basis at 20% per annumwith no residual value.Prepare the journal entry to recognise the patent in the financialstatements of Khair Ltd on 1 July 2020.Narrations are requiredarrow_forwardEco Plastics Company has been revolutionizing plastic and trying to do its part to save the environment. Eco’s founder, Marion Cosby, developed a biodegradable plastic that her company is marketing to manufacturing companies throughout the southeastern United States. After operating as a private company for six years, Eco went public in 2009 and is listed on the Nasdaq stock exchange. As the chief financial officer of a young company with lots of investment opportunities, Eco’s CFO closely monitors the firm’s cost of capital. The CFO keeps tabs on each of the individual costs of Eco’s three main financing sources: long-term debt, preferred stock, and common stock. The target capital structure for ECO is given by the weights in the following table: Source of capital weight Long term debt 30 % Preferred stock 20 % Common stock equity 50 % Total 100 % At the present time, Eco can raise debt by selling 20-year bonds with a $1,000 par value and a 10.5%…arrow_forwardEco Plastics Company has been revolutionizing plastic and trying to do its part to save the environment. Eco’s founder, Marion Cosby, developed a biodegradable plastic that her company is marketing to manufacturing companies throughout the southeastern United States. After operating as a private company for six years, Eco went public in 2009 and is listed on the Nasdaq stock exchange. As the chief financial officer of a young company with lots of investment opportunities, Eco’s CFO closely monitors the firm’s cost of capital. The CFO keeps tabs on each of the individual costs of Eco’s three main financing sources: long-term debt, preferred stock, and common stock. The target capital structure for ECO is given by the weights in the following table: Source of capital weight Long term debt 30 % Preferred stock 20 % Common stock equity 50 % Total 100 % At the present time, Eco can raise debt by selling 20-year bonds with a $1,000 par value and a 10.5%…arrow_forward
- NCO Berhad (NCO) is a manufacturer of high-quality tools for those working in the engineering industry. The mission statement of the company declares that it is dedicated to maximizing the wealth of its shareholders and, since it was formed in 2019, the company has grown rapidly. Recently, the company has developed a new type of drill and the directors of the company are now considering whether this drill should be manufactured and sold. The following information is available to help evaluate the viability of the new product: i. Costs incurred in designing and developing the new drill, which have all been paid, were RM300,000. These costs are to be written off in equal instalments against profits generated over the new product s expected life of four years. ii. Sales are expected to be 20,000 drills per year over the next four years. The selling price of each drill will be RM50 in the first three years and RM40 in the final year. iii. Variable operating costs are estimated to be RM20…arrow_forwardHumanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…arrow_forwardHumanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…arrow_forward
- Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…arrow_forwardHumanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…arrow_forwardHumanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…arrow_forward
arrow_back_ios
SEE MORE QUESTIONS
arrow_forward_ios
Recommended textbooks for you
Principles of Accounting Volume 2AccountingISBN:9781947172609Author:OpenStaxPublisher:OpenStax College
Cornerstones of Cost Management (Cornerstones Ser...AccountingISBN:9781305970663Author:Don R. Hansen, Maryanne M. MowenPublisher:Cengage LearningBusiness/Professional Ethics Directors/Executives...AccountingISBN:9781337485913Author:BROOKSPublisher:Cengage
Auditing: A Risk Based-Approach to Conducting a Q...AccountingISBN:9781305080577Author:Karla M Johnstone, Audrey A. Gramling, Larry E. RittenbergPublisher:South-Western College Pub
Principles of Accounting Volume 2
Accounting
ISBN:9781947172609
Author:OpenStax
Publisher:OpenStax College
Cornerstones of Cost Management (Cornerstones Ser...
Accounting
ISBN:9781305970663
Author:Don R. Hansen, Maryanne M. Mowen
Publisher:Cengage Learning
Business/Professional Ethics Directors/Executives...
Accounting
ISBN:9781337485913
Author:BROOKS
Publisher:Cengage
Auditing: A Risk Based-Approach to Conducting a Q...
Accounting
ISBN:9781305080577
Author:Karla M Johnstone, Audrey A. Gramling, Larry E. Rittenberg
Publisher:South-Western College Pub